BCG predicts rising temperatures will increase default risk in 30% of agri and housing loans by 2030, highlighting climate ...
GlobalData on MSN3d
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancerImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...
Bizcommunity.com on MSN9d
BCG survey reveals untapped market potential of women-centric products and servicesA new BCG survey highlights significant dissatisfaction among women with consumer goods, financial services, and healthcare ...
The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...
In a tight economy, disciplined cost management is often a better path than absorbing margin pressures or passing costs to ...
The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.
ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an "alternative source ...
In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated they were unable to treat patients in the last 12 months due to a lack of access to TICE® BCG. The alternative BCG source has ...
Climate change poses a significant risk to agricultural and housing loans, with default probability increasing due to rising ...
The authorization was granted to ImmunityBio, the manufacturer of Anktiva ® (nogapendekin alfa inbakicept-pmln), an interleukin-15 receptor agonist, indicated with BCG for adult patients with BCG ...
10hon MSN
Rising temperatures and climate change may increase default risks in 30% of agricultural and housing loans in the next five ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback